Effect of alum co-adjuvantation of oil adjuvant vaccine on emulsion stability and immune responses against haemorhagic septicaemia in mice

  • Sujeet Kumar Kakdwip Research Centre, Central Institute of Brackishwater Aquaculture, Kakdwip, 24 PGs (S), West Bengal, India.
  • VinodKumar Chaturvedi BP division, Indian Veterinary Research Institute, Bareilly, India.
  • Bablu Kumar BP division, Indian Veterinary Research Institute, Bareilly, India.
  • Pankaj Kumar Department of Microbiology, Bihar Veterinary College, Patna, India.
  • SudhaRani Somarajan Post doctorate fellow, Health center, University of Texas, Texas, USA.
  • AnilKumar Mishra Goat Health Division, Central Institute for Research on Goats, Makdum, UP, Inida.
  • Bhaskar Sharma ICAR National professor, Division of Biochemistry, IVRI, Bareilly, India.
Alum, Emulsion stability, Haemorrhagic septicaemia, Immune response, Oil adjuvant vaccine, Pasteurella multocida


Background and Objectives: Haemorrhagic septicaemia (HS), caused by Pasteurella multocida, is the most important bacterial disease of cattle and buffaloes in India. Oil adjuvant vaccine (OAV) is the most potent vaccine available for the control of HS. The study aims to evaluate the effect of alum co-adjuvantation of OAV on emulsion stability and immune response.
Materials and Methods: Two different oil adjuvant vaccines viz., standard oil adjuvant vaccine (OAV) and alum precipitated oil adjuvant vaccine (A–OAV) were prepared with Pasteurella multocida antigen. Emulsion stability was tested by centrifugation, storage at 37 oC for 3 months and microscopy. Immune responses were evaluated by ELISA antibody titer, CD4, CD8 T cell populations and survival post challenge by P. multocida in mice.
Results: The separation of aqueous and oil phase of emulsion by centrifugation and storage test were 0 and 6.76% in A-OAV as compared to 11.00 and 26.39% in OAV, respectively. The mean droplet size was significantly smaller (p<0.01) in A–OAV as compared to OAV. The A–OAV recorded higher ELISA antibody titer (p<0.05) up to 21st days post vaccination, and higher CD4 (p>0.05) and CD8 T cell (p<0.05) populations compared to OAV. The A–OAV group conferred 100% protection after challenge with both 100 LD50 and 1000 LD50 as compared to 100 and 60% respective protection by OAV group.
Conclusion: The results indicates that A–OAV had better emulsion stability, produces higher level of CD4, CD8 T cells and antibody titer with better protection compared to oil adjuvant vaccine.


Muneer R, Hussain M, Zahoor A. Efficacy of Oil Based Haemorrhagic Septicaemia Vaccine: A Field Trial. Int J Agr Biol 2005; 7: 571–573.

Shah NH, Shah NH, de Graaf FK. Protection against haemorrhagic septicaemia induced by vaccination of buffalo calves with an improved oil adjuvant vaccine. FEMS Microbiol Lett 1997; 155: 203–207.

Dutta J, Rathore B, Mullick S, Singh R, Sharma G.Epidemiological studies on occurrence of haemorrhagic septicaemia in India. Indian Vet J 1990; 67: 893–899.

Bowersock TL, Martin S. Vaccine delivery to animals.Adv Drug Deliver Rev 1999; 38: 167–194.

Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19:2666–2672.

Chang JCC, Diveley JP, Savary JR, Jensen FC.Adjuvant activity of incomplete Freund's adjuvant. Adv Drug Deliver Rev 1998; 32: 173–186.

Cox JC, Coulter AR. Adjuvants--a classification and review of their modes of action. Vaccine 1997; 15:248–256.

Lindblad EB. Aluminium adjuvants--in retrospect and prospect. Vaccine 2004; 22: 3658–3668.

De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J immunol 2008; 38: 2068–2071.

Freund J, Thomson KJ. Antibody formation and sensitization with the aid of adjuvants. J Immunol 1948; (Baltimore, Md.: 1950) 60: 383–398.

Xiao C, Rajput ZI, Hu S. Improvement of a commercial foot-and-mouth disease vaccine by upplement of Quil A. Vaccine 2007; 25: 4795–4800.

Song X, Bao S, Wu L, Hu S. Ginseng stem–leaf saponins (GSLS) and mineral oil act synergistically to enhance the immune responses to vaccination against foot-and-mouth disease in mice. Vaccine 2009; 27:51–55.

Thorley C, Egerton J. Comparison of alum-absorbed or non-alum-absorbed oil emulsion vaccines containing either pilate or non-pilate Bacteroides nodosus cells in inducing and maintaining resistance of sheep to experimental foot rot. Res Vet Sci 1981; 30: 32–37.

Richards RL, Rao M, Vancott TC, Matyas GR, Birx DL, Alving CR. Liposome-stabilized oil-in-water emulsions as adjuvants: increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen. Immunol cell Biol 2004; 82:531–538.

Aronson MP, Petko MF. Highly concentrated water- in-oil emulsions: Influence of electrolyte on their properties and stability. J Colloid Interf Sci 1993; 159:134–149.

Marquez AL, Medrano A, Panizzolo LA, Wagner JR.Effect of calcium salts and surfactant oncentration on the stability of water-in-oil (w/o) emulsions prepared with polyglycerol polyricinoleate. J Colloid Interf Sci 2010; 341: 101–108.

Jiang J, Mei Z, Xu J, Sun D. Effect of inorganic electrolytes on the formation and the stability of water- in-oil (W/O) emulsions. Colloids Surf A Physicochem Eng Asp 2013; 429: 82–90.

Mishra R. Manual of production of hemorrhagic septicaemia vaccine. FAO UNDP: 1985; 24.

OIE. Haemorrhagic septicaemia. OIE Terrestrial Mannual chapter 2008; 2.4.12:739–751.

Mowat N, Rweyemamu M. Vaccine manual: the production and quality control of veterinary vaccines in developing countries. FAO Animal Production and Health series number 35 Rome 1997; p433.

Koh Y, Higgins S, Weber J, Kast WM. Immunological consequences of using three different clinical/ laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med 2006; 4: 42–42.

Drugs and cosmetics acts and rules (VI amendment)1994; Government of India.

Briggs D, Skeeles J. An enzyme-linked immunosorbent assay for detecting antibodies to Pasteurella multocida in chickens. Avian Dis 1984; 28: 208–215.

Reed LJ, Muench H. A simple method of estimating 50 percent endpoints. Am J Hyg 1938; 27: 493–497.

Paulson DS. Biostatistics and Microbiology: A Survival Manual. Springer Science-Business Media publication, New York, USA. 2008 pp. 63-81.

Chandrasekaran S, Kennett L, Yeap PC, Muniandy N, Rani B, Mukkur TKS. Characterization of immune response and duration of protection in buffaloes immunized with haemorrhagic septicaemia vaccines. Vet Microbiol 1994; 41(3): 213-219.

Jansen T, Hofmans MPM, Theelen MJG, Schijns VEJC.Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine 2005; 23: 1053–1060.

Kumar S, Chaturvedi VK, Kumar B, Kumar P. Immune response and viscosity of haemorrhagic septicaemia oil adjuvant vaccine at different water-oil proportion. Indian J Anim Sci 2011; 81: 1000–1004.

Verma R, Jaiswal TN. Haemorrhagic septicaemia vaccines. Vaccine 1998; 16: 1184–1192.

Kumar S, Chaturvedi VK, Kumar B, Kumar P, Somarajan SR, Kumar A, Yadav AS, Sharma B. Improved humoral immune response of oil adjuvant vaccine by saponin co-adjuvantation against haemorrhagic septicaemia in mice and buffalo calves. Indian JAnim Sci 2012; 82:953-957.

Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol 2010; 31: 103–109.

How to Cite
Kumar S, Chaturvedi V, Kumar B, Kumar P, Somarajan S, Mishra A, Sharma B. Effect of alum co-adjuvantation of oil adjuvant vaccine on emulsion stability and immune responses against haemorhagic septicaemia in mice. Iran J Microbiol. 7(2):79-87.
Original Article(s)